Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2011

View Archived Issues

Omalizumab data in food allergy, urticaria, atopic dermatitis and geriatric asthma reported

Phase I data reveal protective effects for MnSOD-PL in chemoradiotherapy-treated NSCLC

Nanodiamond-conjugated doxorubicin associated with enhanced efficacy and improved safety

Novel antibacterial agents patented by AstraZeneca

N30 Pharma's GSNOR inhibitors show promise for the treatment of asthma

Astellas Pharma discloses potent, orally bioavailable TRPV1 antagonists

Liver-targeted SCD inhibitor from Merck & Co. shows improved tolerability

Chiesi scientists prepare new glucocorticoid receptor ligands

Novel tyrosine-protein kinase inhibitors patented by Chinese scientists

Allergan researchers present novel tyrosine-protein kinase inhibitors

Lundbeck begins phase I trials for Lu-AF-11167

Benzodiazepine derivatives for hepatitis C infection designed at Arrow Therapeutics

Concert Pharmaceuticals begins phase I trial of chronic kidney disease treatment CTP-499

Faes Farma launches antihistamine bilastine in Spain

Newron and Merck Serono expand research collaboration for CNS therapies

INX-189 shows promising safety and antiviral profile in phase Ib trial

Phase IIa results for Achillion's ACH-1625 show rapid virologic response in chronic HCV

Regulus receives intellectual property license to modulate microRNAs

BioSante completes enrollment in second pivotal phase III LibiGel trial

Daiichi Sankyo and Kitasato Institute to launch joint vaccine venture

Phase III trials of OMS-103HP do not meet prespecified endpoints

FDA grants fast track designation for cenderitide for post-acute HF indication

Phase IIb/III trial of tasimelteon in MDD planned for second half of 2011

Amgen requests reexamination of CHMP opinion on Vectibix with chemotherapy for mCRC

Intercell and Novartis to advance Pseudomonas aeruginosa vaccine program

CorMedix provides update on phase II study of CRMD-001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...